Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey — April 14, 2026 – Apotex Corp. today announced

Parenteral and Sterile Fill-Finish Development and Manufacturing Trends

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral/sterile drug product manufacturers.

Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)

Whippany, NJ – January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to

Halo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment

Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online

Halo Pharma nomme Laurent Malgouyres directeur du site de Mirabel, au Canada.

Whippany, NJ – October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will

John Bender rejoint Woodstock Sterile Solutions, Halo Pharma, en tant que vice-président du développement commercial

Woodstock, IL, August 12, 2025  Bender brings 35 years of pharmaceutical industry experience to dual role Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development

Le groupe Noramco investit 104 025 millions de dollars dans l'usine de Whippany de Halo Pharma pour y proposer la fabrication de produits injectables stériles.

WILMINGTON, Del. and WHIPPANY, New High-Speed Filling Line to Support Growing Demand for Sterile Injectables and Strengthen Domestic Supply Chain Learn More About Halo Pharma’s